J.C. Pancreatic Cancer

ANSWER

Case Study Analysis: J.C. Pancreatic Cancer
1. Possible Common Sites for J.C.’s Metastasis and Justification
Pancreatic ductal adenocarcinoma most commonly metastases from:

Liver: The most often occurring site of metastases is the liver since direct blood flow from the pancreas passes via the portal vein.
Hematogenous spread lets tumour cells get to the pulmonary vasculature.
The pancreas is near the peritoneal cavity, hence direct invasion or peritoneal seeding is a frequent way for metastases.
Lymphatic spread often involves mesenteric and peripancreatic lymph nodes.
The physical links of the pancreas to the lymphatic and arterial systems, which help tumour cells to spread, make these areas prone to metastases.

2. Tumour Cell Markers and Their Significance Regarding Pancreatic Cancer
Tumour cell markers are biomolecules created by either the body in reaction to malignancy or cancer cells. They help in diagnosis, prognosis, and tracking therapy’s efficacy.

Common Markers for Pancreatic Cancer: Carbohydrate Antigen 19-9 raised in most cases of pancreatic cancer, it facilitates identification and monitoring of treatment response.
Useful in prognosis and disease progression, CEA (Carcinoembryonic Antigen)
Why Designed:

They support the diagnosis confirmation in line with imaging and biopsy results.
They help to evaluate the stage of disease and tumour load.
Their use helps to track therapy effectiveness and identify recurrence.
Ordering CA 19-9 for J.C. would give him important new perspectives on the development of the tumour and response to treatment.

3. TNM Stage Classification for Tumour of J.C.
Cancer is staged using TNM (Tumour, Node, Metastasis) classification system depending on tumour size, lymph node involvement, and distant metastases.

Tumour, or T:

J.C. classified her 4 cm mass invading the superior mesenteric vein and Wirsung duct as T3 (tumour spreads beyond the pancreas but without involvement of the celiac axis or superior mesenteric artery).
Node N:

Classed as N1 (regional lymph node involvement), a 1.5 cm perilesional lymph node with metastatic features
Metastasis (M) :

This is classed as M0 since no distant metastases are observed.
T3N1M0, Stage III TNM Classification for J.C

The Value of Classification:

directs therapy plans (such as palliative care, neoadjuvant chemotherapy).
Forecasts; Stage III indicates advanced but localised disease.
Standardises research comparisons and improves physician communication.
4. Features of Harmful Tumours
Like ductal adenocarcinoma, malignant tumours show the following:

Poor differentiation and aberrant shape define cellular properties.
More nuclear-to—cytoplasmic ratio and regular mitotic counts.
Developmental Behaviour:
quick and unrestrained spread.
Attack of nearby tissues (in J.C.’s case, superior mesenteric vein).
Possibility of local invasion into nearby buildings.
Lymphatic spread to local lymph nodes.
Hematogenous dissemination to far-off organs (such as lungs, liver).
These features make aggressive malignant tumours difficult to control and call for multimodal treatment strategies.

5. Cancerism Phase of Metallosis
In carcinogenesis, metastases develop throughout the phase of progression. In this phase:

Tumour cells cause the development of fresh blood vessels to support fast expansion.
Tumour cells destroy extracellular matrix proteins, hence invading adjacent tissues.
Cells pass into lymphatic veins or the circulation.
Travelling to far-off places, circulating tumour cells avoid immune destruction.
Tumour cells leave the arteries to start secondary tumours in organs like the liver or lungs.
The tumour of J.C has progressive traits shown by lymph node metastases and mesenteric vein intrusion.

Six: Level Affected in Tissue
For J.C., the tissue level impacted is epithelial tissue.

rationale:

Beginning in the epithelial cells lining the pancreatic ducts, pancreatic ductal adenocarcinoma occurs.
In this tumour, epithelial cells undergo mutations causing uncontrollably rapid proliferation, lack of differentiation, and invasive behaviour.
In conclusion
J.C.’s case emphasises a characteristic picture of advanced pancreatic ductal adenocarcinoma including local infiltration and regional lymph node involvement. Knowing tumour markers, TNM classification, metastatic paths, and how malignant tumours behave helps one to appreciate the difficulty in treating pancreatic cancer. Improving results in such aggressive cancers depends on early identification, exact staging, and focused treatments.

Allusions
In 2019 McCance, K. L., Huether, S. E., Brashers, V. L., & Rote, N. S. Pathophysiology: The biologic foundation of disease in adults and children (8th ed.). Other Thanvier.
2020 Siegel, R. L.; Miller, K. D.; Jemal, A. 2020 cancer statistics. CA: A Cancer Journal for Clinicians, seventy-one (1), 7–30. https://doi.org/10.3322/caac.21590

 

 

 

 

QUESTION

J.C is an 82-year-old white man who was evaluated by GI specialist due to abdominal discomfort, loss of appetite, weight lost, weakness and occasional nausea.

Past Medical History (PMH):
Patient is Diabetic, controlled with Metformin 500 mg by mouth twice a day, Lantus 15 units SC bedtime. Hypertensive, controlled with Olmesartan 20 mg by mouth once a day. Atrial Fibrillation, controlled with Rivaroxaban 15 mg by mouth once a day and bisoprolol 10 mg by mouth once a day.

Labs:
Hb 12.7 g/dl; Hct 38.8% WBC 8.2; Glycemia 74mg/dl; Creatinine 0.8 mg/dl; BUN 9.8 mg/dl; AST 21 U/L ALT 17 U/L; Bil T 1.90 mg/dl; Ind 0.69 mg/dl; Dir 1.21 mg/dl.

Diagnostic test:
Endoscopic Ultrasound of the Pancreas. Solid mass in the head of pancreas 4 cms, infiltrating Wirsung duct. The solid mass impress to infiltrate the superior mesenteric vein. Perilesional node is detected, 1.5 cms, metastatic aspect. Fine needle aspiration (FNA) biopsy: Ductal adenocarcinoma.

Case study questions:

  1. Please name the potential most common sites for metastasis on J.C and why?
  2. What are tumor cell markers and why tumor cell markers are ordered for a patient with pancreatic cancer?
  3. Based on the case study described, proceed to classify the tumor based on the TNM Stage classification. Why this classification important?
  4. Discussed characteristic of malignant tumors regarding it cells, growth and ability to spread.
  5. Describe the carcinogenesis phase when a tumor metastasizes.
  6. Choose the tissue level that is affected on the patient discussed above: Epithelial, Connective, Muscle or Neural. Support your answer.

Submission Instructions:

  • Your initial post should be at least 500 words, formatted and cited in current APA style with support from at least 2 academic sources.
Scroll to Top